Novaliq GmbH
Novaliq is a private pharmaceutical company developing transformational ocular therapies using unique water-free technology for conditions like diabetic retinopathy.
Classification
Profile
Funding
Funding details not yet available.
Transforms ocular therapies via unique water-free technology, revolutionizing treatment paradigms for conditions like Diabetic Retinopathy.
Patients suffering from ocular diseases such as Diabetic Retinopathy, accessed through healthcare providers and pharmaceutical channels.
Sales of transformational ocular therapies and new drug categories developed through its proprietary water-free technology platform.
Direct distribution of pharmaceutical products to healthcare markets; specific sales motion details are not provided in the snippets.
Information insufficient. Snippets mention R&D programs but do not specify strategic alliances or distribution partners.
Primary costs are driven by R&D for novel drug candidates with distinct modes-of-action and development of the water-free technology.
Proprietary water-free technology platform, novel drug candidates, and expertise in diabetic retinopathy pathophysiology.
Developing transformational ocular therapies, conducting R&D on novel drug candidates, and leveraging water-free technology for topical treatments.
Information insufficient. Snippets describe the technology and disease focus but do not detail customer acquisition or retention models.
Competes in the ophthalmic pharmaceutical space by offering a new drug category via water-free technology, differentiating from established treatments.
Limited efficacy or convenience of existing treatments for Diabetic Retinopathy and other ocular conditions, addressed by novel topical therapies.
- Expand Real-World Evidence (RWE) Program - Deploy a digital adherence app linked to EHR data to capture outcomes, strengthen payer negoti
Map KOL Influence: Identify top 10 ophthalmology influencers on LinkedIn and Twitter; schedule joint webinars within Q3 2026 · Pilot RWE App: Launch a beta version with 5 US eye-care clinics to collect adherence and symptom-resolution data by Q1 2027 · Negotiate Asia-Pacific Licensing: Target at least two regional pharma partners by end of 2026, fo
- Regulatory Success: FDA clearance (2023) and multiple CE marks demonstrate robust clinical validation and de-risk for investors and partn
Team details not yet available.
No investors recorded yet.